Frederic Jacques de Bure
Direktor/Vorstandsmitglied bei Inpellis, Inc.
Profil
Frederic Jacques de Bure is an Independent Director at Inpellis, Inc. and a General Partner at Nusantara Ventures Singapore Pte Ltd.
He was previously a Non-Affiliated Director at PT Visi Media Asia Tbk.
Mr. de Bure holds an MBA from The University of Chicago and an undergraduate degree from Vassar College.
Aktive Positionen von Frederic Jacques de Bure
| Unternehmen | Position | Beginn |
|---|---|---|
| Nusantara Ventures Singapore Pte Ltd. | Corporate Officer/Principal | 01.01.2009 |
Inpellis, Inc.
 Inpellis, Inc. Pharmaceuticals: MajorHealth Technology Inpellis, Inc. operates as a specialty pharmaceutical company that focuses on developing and commercializing transdermal prescription therapeutics for treating acute and chronic pain resulting from musculoskeletal disorders and peripheral neuropathy. Its products include transdermal ibuprofen for moderate to severe osteoarthritis and transdermal benfotiamine for painful diabetic neuropathy. The company was founded in 2012 and is headquartered in Haddonfield, NJ. | Direktor/Vorstandsmitglied | 01.01.2015 |
Ehemalige bekannte Positionen von Frederic Jacques de Bure
| Unternehmen | Position | Ende |
|---|---|---|
| PT VISI MEDIA ASIA TBK | Corporate Officer/Principal | 20.03.2012 |
Ausbildung von Frederic Jacques de Bure
| The University of Chicago | Masters Business Admin |
| Vassar College | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| PT VISI MEDIA ASIA TBK | Consumer Services |
| Private Unternehmen | 2 |
|---|---|
| Nusantara Ventures Singapore Pte Ltd. | |
Inpellis, Inc.
Inpellis, Inc. Pharmaceuticals: MajorHealth Technology Inpellis, Inc. operates as a specialty pharmaceutical company that focuses on developing and commercializing transdermal prescription therapeutics for treating acute and chronic pain resulting from musculoskeletal disorders and peripheral neuropathy. Its products include transdermal ibuprofen for moderate to severe osteoarthritis and transdermal benfotiamine for painful diabetic neuropathy. The company was founded in 2012 and is headquartered in Haddonfield, NJ. | Health Technology |
